ĐÁNH GIÁ HIỆU QUẢ SỚM CỦA CAN THIỆP NỘI MẠCH TRONG ĐIỀU TRỊ TĂNG SINH LÀNH TÍNH TUYẾN TIỀN LIỆT

Abstract

Objective: To evaluate the early efficacy of prostatic artery embolization (PAE) in the treatment of benign prostatic hyperplasia (BPH). Subject and Methods: A descriptive case series study was conducted on 47 patients diagnosed with BPH who underwent PAE at Tam Anh General Hospital, Ho Chi Minh City, from September 2022 to August 2024. Treatment efficacy was assessed based on changes in the International Prostate Symptom Score (IPSS), quality of life (QoL) score, prostate volume, post-void residual urine volume (PVR), and clinical response at 3 and 6 months post-intervention. Results: The mean IPSS before intervention was 28.4 ± 2.9; it decreased by 51.1% at 3 months and by 53.5% at 6 months post-intervention. The mean QoL score was 4.6 ± 0.6 before intervention, with a reduction of 39.1% at 3 months and 43.5% at 6 months. The average prostate volume was 78.6 ± 28.5 mL before intervention, decreasing by 23.9% at 3 months and by 37.5% at 6 months. The mean PVR was 75 ± 82.0 mL before intervention, with a reduction of 42.4% at 3 months and 69.8% at 6 months. The overall clinical response rate at both 3 and 6 months was 87.2%. The rate of minor complications was 17%, with urinary tract infections accounting for 12.8%. Conclusion: Prostatic artery embolization is a minimally invasive, safe, and effective treatment modality that significantly improves lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia.